Drug intelligence / Profile preview

KB295

Development stage: Discontinued
Lead developer: Kaleido Biosciences
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

KB295 is a synthetic glycan developed by Kaleido Biosciences as a Microbiome Metabolic Therapy (MMT™) for the treatment of ulcerative colitis. It is designed to modulate the gut microbiome by acting as a specific growth substrate for beneficial bacteria while depleting pathobionts. In clinical and ex vivo studies, KB295 has been shown to increase the production of short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, and reduce the relative abundance of the Enterobacteriaceae family. The drug was evaluated in an exploratory, open-label clinical study (NCT04508413) in patients with mild-to-moderate ulcerative colitis, where it demonstrated safety, tolerability, and a reduction in inflammatory biomarkers like fecal calprotectin and lactoferrin. Development was halted following Kaleido Biosciences' cessation of operations in 2022.

Beyond the preview

Go deeper on KB295.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KB295.

Explore the full profile